Both programmes demonstrate Exscientia’s ability to design highly differentiated, potentially best-in-class molecules Exscientia will receive $15 million for achieving these milestones and is eligible for over $600 million in additional milestone payments for these two programmes as well as high-single-digit to mid-teen royalties Three programmes in the partnership have now advanced through initial milestones with multiple... Read More

Demonstrated combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies Data highlights efficacy of ‘539 in a preclinical AML model, with limited impact on platelet levels Identified PD biomarkers related to LSD1 inhibitor treatment OXFORD, England / Oct 09, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36 th EORTC-NCI-AACR (ENA) Symposium... Read More

OXFORD, England / Aug 28, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 7:00 a.m. EDT (12:00 p.m. BST). A live webcast of the fireside chat will be available on the Company’s website,... Read More

Entered into definitive agreement to combine with Recursion to create a global technology-enabled drug discovery leader with end-to-end capabilities Acquired full rights to GTAEXS617 (CDK7 inhibitor), with initial Phase I monotherapy data expected in 2H24 Launched AWS AI-powered platform to advance drug discovery LSD1 and MALT1 inhibitor programmes continue to progress towards the clinic, on track for 2H24 IND/CTA... Read More

Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to commence in late 2024/early 2025 OXFORD, England / Jul 18, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced it has reached an... Read More

State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost OXFORD, England / Jul 10, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced it will be expanding its work with Amazon Web Services (AWS) to use the cloud... Read More

AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief Medical Officer, adding extensive oncology drug development expertise to execute robust clinical strategy on Exscientia’s internal oncology pipeline OXFORD, England / Jun 06, 2024 / Business Wire / Exscientia plc... Read More

OXFORD, England / May 30, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June: Barclays Digital and Disruptive Technology Conference. Panel on Tuesday, June 11, 2024 at 9:45 a.m. BST in London, England Goldman Sachs 45 th Annual Global Healthcare Conference. Fireside chat on Tuesday, June 11, 2024 at... Read More

Positive early Phase 1 results for BMS-partnered programme ‘4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2H24 LSD1 and MALT1 inhibitor programmes expected to advance into clinic in 2H24 and early 2025, respectively AI-design integration enhanced with full experiment automation driving towards maximum speed, quality and autonomous drug design Leveraging technology advancements and... Read More

Company to host conference call and webcast on May 21, 2024, at 1:30 p.m. BST / 8:30 a.m. EDT OXFORD, England / May 14, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and... Read More

OXFORD, U.K. / Mar 21, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below. Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT. “In 2023, we significantly expanded our technological capabilities with the opening of... Read More

Company to host conference call and webcast on March 21, 2024, at 12:30 p.m. GMT / 8:30 a.m. EDT OXFORD, England / Mar 14, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2023, on Thursday, March 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a... Read More

OXFORD, England / Feb 28, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March: TD Cowen 44 th Annual Health Care Conference. Fireside chat on Wednesday, March 6, 2024 at 2:10 p.m. EST (7:10 p.m. GMT) in Boston, Massachusetts Barclays 26 th Annual Global Healthcare Conference. Fireside chat on Tuesday, March... Read More

Multicentre EXCYTE-2 study to evaluate precision medicine platform in patients with acute myeloid leukaemia Supports ongoing development of LSD1 inhibitor (EXS74539) currently in preclinical development OXFORD, England / Feb 07, 2024 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-2, an observational clinical study in acute myeloid leukaemia (AML) to investigate the relationship... Read More

Distinguished honour for Exscientia’s founder and Chief Executive Awarded in the 2024 New Year Honours List by HM King Charles III Follows multiple recent recognitions for outstanding personal achievements and those of Exscientia OXFORD, England / Jan 02, 2024 / Business Wire / Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been appointed Commander of the Order of the... Read More

The programme aims to design a potential best in class molecule by combining Exscientia's research platform with Sanofi's leading development expertise Exscientia eligible for additional upfront and research stage milestones on top of existing agreement OXFORD, England / Dec 21, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that Sanofi is adding a new discovery stage programme identified and initially... Read More

$2.3 million grant expected to drive research to harness the host interferon response as a pathway to treating and preventing pandemic influenza OXFORD, England / Dec 05, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing. Under this grant, Exscientia aims to... Read More

OXFORD, England / Nov 21, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the 6 th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 3:25 p.m. EST (8:25 p.m. GMT). A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at... Read More

OXFORD, U.K. / Nov 09, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below. Exscientia will host a conference call Thursday, November 9 at 1:30 p.m. GMT / 8:30 a.m. EST. “At Exscientia, we are laser-focused on building an engine that designs and develops high impact... Read More

Company to host conference call and webcast on November 9, 2023, at 1:30 p.m. GMT / 8:30 a.m. EST OXFORD, England / Nov 02, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. EST to provide a business... Read More

Renowned technology champion to strengthen company’s development of precision medicine and clinical innovation platforms OXFORD, U.K. / Oct 17, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024. In this newly established role, Parker will lead the creation and execution of a focused corporate... Read More

Demonstrated preclinical efficacy of LSD1 inhibitor in primary AML samples Initial data supporting combination potential of LSD1 inhibitor with AML standard of care therapies Tumour growth inhibition through MALT1 in monotherapy and combination while lowering bilirubin toxicity risk OXFORD, England / Oct 16, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced two abstracts to be presented at the upcoming... Read More

Concentrating rapidly emerging pipeline on most differentiated, highest value oncology targets, including CDK7 and LSD1 programmes Partnering or discontinuing internal development of programmes outside of core focus, including A 2A and select discovery targets Strategy will support continued investment into market-leading technology while maintaining cash runway well into 2026 Partnered pipeline continues to progress with... Read More

Collaboration will leverage Exscientia’s precision design capabilities to focus on previously unsolved drug design challenges Exscientia is eligible to receive up to $674 million in discovery, development, regulatory and sales-based milestones for three projects, in addition to single to double digit royalty payments on net sales Up to $113 million of potential milestone payments in the discovery phase, with $20 million... Read More

OXFORD, England / Aug 31, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in September: 2023 Wells Fargo Healthcare Conference. Fireside chat on Thursday, September 7, 2023, at 3:45 p.m. EDT (8:45 p.m. BST) in Boston, Massachusetts Morgan Stanley Global Healthcare Conference 2023 . Formal presentation on... Read More

OXFORD, U.K. / Aug 10, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below. Exscientia will host a conference call Thursday, August 10 at 1:30 p.m. BST / 8:30 a.m. EDT. “In the first half of 2023, four molecules precision-designed by Exscientia advanced... Read More

Company to host conference call and webcast on August 10, 2023, at 1:30 p.m. BST / 8:30 a.m. EDT OXFORD, England / Aug 03, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) will report financial results for the second quarter ended June 30, 2023, on Thursday August 10, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update... Read More

First multi-centre trial, EXCYTE-1, evaluating the potential of Exscientia’s functional precision medicine platform in solid tumour indication Builds off of pioneering AI-guided functional precision medicine research in haematological cancers OXFORD, England & VIENNA, Austria / Jul 18, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-1, a prospective observational study in ovarian... Read More

Preclinical data from AI-optimized GTAEXS617 support potential for improved therapeutic index compared to other CDK7 inhibitors under development Parallel translational initiative to evaluate preclinically identified non-invasive PD biomarkers with potential to predict GTAEXS617 treatment responders SAN FRANCISCO and SHANGHAI, China, July 10, 2023 (GLOBE NEWSWIRE) -- GT Apeiron, a biopharmaceutical company harnessing the... Read More

Expanded leadership structure maintains nimble technology development across multitude of discovery and development functions OXFORD, England / Jun 29, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) announced today that it is expanding its technology management structure to accelerate application of Exscientia's innovative technologies to catalyse instrumental change in the way drug candidates are being discovered,... Read More

OXFORD, England / May 24, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST / 8:30 a.m. EDT. “With our sixth AI-designed compound reaching the clinical development stage plus two more in active... Read More

Latest technology advances to innovate drug design, discovery and development Novel automated discovery laboratory on track to open in 2023 OXFORD, England / May 22, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced two abstracts for oral and poster presentation, as well as the closing keynote to be delivered at the Society for Laboratory Automation and Screening (SLAS) Europe Conference and Exhibition... Read More

Company to host conference call and webcast on May 24, 2023, at 1:30 p.m. BST / 8:30 a.m. EDT OXFORD, England / May 17, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 24, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and... Read More

Third clinical molecule from collaboration with Sumitomo Pharma to enter Phase 1 trials DSP-2342, a dual 5-HT2A/5-HT7 antagonist to be assessed in psychiatric disease OXFORD, England / May 15, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced that Sumitomo Pharma Co., Ltd. (‘Sumitomo Pharma’) plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective... Read More

Renowned thought leader in computational biology and data science for cancer research Over 180 publications on the evolutionary dynamics of cancer initiation, progression, response to therapy and emergence of resistance OXFORD, England / May 03, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors. Prof. Michor is a professor of... Read More

Includes recent advancements from precision designed compounds Functional personalised medicine platform unveiling unique adenosine biomarker to enrich for patients more likely to respond to treatment OXFORD, England / Apr 19, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) today announced four presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14-19, 2023 in... Read More

OXFORD, U.K. / Mar 23, 2023 / Business Wire / Exscientia plc (Nasdaq: EXAI) Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below. Exscientia will host a conference call today, March 23, at 12:30 p.m. GMT / 8:30 a.m. EDT. "2022 was marked by significant milestones for Exscientia, including signing a... Read More

Company to host conference call and webcast on March 23, 2023 at 12:30 p.m. GMT / 8:30 a.m. EDT Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results. A... Read More

Abstracts highlight pipeline programmes in precision oncology, including novel LSD1 inhibitor Further detail on A 2A programme, including novel biomarker for patient selection to be presented Exscientia plc (Nasdaq: EXAI) today announced that four abstracts have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023, at the... Read More

Precision designed LSD1 and MALT1 inhibitors currently progressing through IND-enabling studies Both molecules demonstrate Exscientia’s ability to overcome critical design challenges and identify high quality drug candidates with potential increased probability of success Company on track to meet target of four molecules in clinical development by 2024 Watch video presentation reviewing both compounds Exscientia plc (Nasdaq:... Read More

Partnership will further validate Exscientia’s functional drug testing platform to predict response in haematological cancers Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charité – Universitätsmedizin Berlin (Charité) to utilise Exscientia’s AI-driven precision medicine platform in haematological cancers. Under the collaboration, Charité will evaluate the potential of Exscientia’s precision medicine... Read More

Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March: Morgan Stanley EMEA HealthTech Conference. Management will participate in virtual investor meetings on Wednesday, March 1, 2023 Cowen 43 rd Annual Healthcare Conference . Formal presentation on Tuesday, March 7, 2023, at 11:10 a.m. EST (4:10 p.m. GMT) in Boston, Massachusetts... Read More

EXS4318 is the first immunology & inflammation candidate designed by Exscientia and its fourth molecule to enter the clinic Exscientia invented a potentially first-in-class potent and selective PKC theta inhibitor Eligible for pre-commercial milestone payments and, if approved, tiered royalties on net product sales Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia... Read More

Uses multi-omics to identify a biomarker which could be predictive of '546 response in the clinic Differentiated '546 development and patient enrichment strategy driven by Exscientia's precision medicine platform Research highlights the relationship between Exscientia's high adenosine biomarker and prediction of checkpoint inhibitor response Recently initiated Phase 1/2 clinical trial, IGNITE-AI, will evaluate biomarker... Read More

Study will enrol up to 110 patients in immunotherapy relapsed/refractory RCC and NSCLC Exscientia’s A 2A biomarker signature for patient selection will be prospectively tested during the trial CTA for GTAEXS-617, Exscientia's CDK7 inhibitor, on track to be submitted in December 2022 Exscientia plc (Nasdaq: EXAI) today announced clinical trial application (CTA) approval of IGNITE-AI, enabling site activation in its first... Read More

Exscientia plc (Nasdaq: EXAI) Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the third quarter 2022, are summarised below. Exscientia will host a conference call today, November 15, at 1:30 p.m. GMT / 8:30 a.m. ET. “At Exscientia, we are working towards the goal of leading the transformation of our industry’s approach to how drugs are created and how we can... Read More

Effort aligns MD Anderson’s drug development expertise with Exscientia’s AI-driven patient-first precision medicine and drug discovery platforms Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in... Read More

Company to host conference call and webcast on November 15, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2022, on Tuesday, November 15, 2022, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. EST, to provide a business update and review financial results. A webcast of... Read More

Fast and accurate generative AI design of novel antibodies extends Exscientia's capabilities beyond small molecules Sequencing paired human antibody data to create better AI models for antibody design Automated laboratory with proprietary hardware to enable integration of AI design with high-throughput biologics profiling under development Exscientia plc (Nasdaq: EXAI) today announced the expansion of its platform to include... Read More

Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November: BofA Securities 2022 A.I. and Disruptive Tech Conference. Fireside chat (AI in Drug Discovery) on Wednesday, November 9, 2022, at 12:40 p.m. EST (5:40 p.m. GMT) 2022 Jefferies London Healthcare Conference. Management will participate in investor meetings on Wednesday, November... Read More

Biopharma industry’s coveted prize recognizes company’s AI-driven precision medicine platform Exscientia plc (Nasdaq: EXAI) is honoured to announce that the company has won the Prix Galien USA 2022 Award for Best Digital Health Solution in recognition of its AI-driven precision medicine platform. The award was presented Thursday at the Prix Galien Forum in New York City. Worldwide, the Prix Galien, which recognizes... Read More

Combines precision oncology platform with single-cell sequencing and transcriptomics with aim to select patients most likely to benefit from GTAEXS-617 therapy Confirmed and identified CDK7-specific pharmacodynamic biomarkers in cancer and immune cells Phase 1/2 clinical trial to validate correlation of signature and response expected to commence in 1H 2023 following planned CTA submission in 4Q 2022 Exscientia plc (Nasdaq:... Read More

Exscientia (Nasdaq: EXAI), ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) today announced a new publication in Blood Cancer Discovery , a journal of the American Association for Cancer Research, titled “Deep Morphology Learning Enhances Precision Medicine by Image-Based Ex Vivo Drug Testing ” from the laboratory of Prof. Berend Snijder. This post-hoc analysis builds on the... Read More

Exscientia plc (Nasdaq: EXAI) today announced that Caroline Rowland has joined Exscientia as Chief People Officer. In this newly created role, she will lead Exscientia’s People (human resources) and Places functions and build on the Company’s talent, training and employee experience strategies. Caroline reports to CEO and Founder, Andrew Hopkins, DPhil. “Exscientia was founded to create an entirely new type of biopharma... Read More

Exscientia (Nasdaq: EXAI) today announced that Company management will participate in the following investor conferences in September: Morgan Stanley Annual Global Healthcare Conference: Date: Wednesday, September 14, 2022 Time: 3:35 p.m. BST / 10:35 a.m. EST Location: New York, New York Participants: Ben Taylor, CFO & Chief Strategy Officer and Dave Hallett, Chief Operations Officer BofA Securities Global Healthcare... Read More

Exscientia plc (Nasdaq: EXAI) Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, August 18 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the company’s pipeline and corporate strategy. “In the first half of 2022, we delivered on... Read More

Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, will report financial results for the second quarter ended June 30, 2022, on Wednesday, August 17, 2022 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. ET on... Read More

Exscientia plc (Nasdaq: EXAI) today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A 2A receptor antagonist ​​co-invented and developed through a collaboration between Exscientia and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; Nasdaq: EVO). Topline data... Read More

Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO, and Dave Hallett, Chief Operations Officer, will participate in a fireside chat at the Goldman Sachs 43 rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 9:20 a.m. P.T. (5:20 p.m. BST). A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at... Read More

Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations, and operations, as well as financial results for the first quarter 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the Company's precision medicine platform. "We started 2022 by commencing a groundbreaking collaboration with... Read More

Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, will report financial results for the first quarter ended March 31, 2022, on Wednesday, May 25, 2022 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. ET on Thursday,... Read More

Exscientia (Nasdaq: EXAI) today announced that Ben Taylor, CFO & Chief Strategy Officer and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:20 p.m. P.T. A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai . An archived... Read More

Exscientia plc (Nasdaq: EXAI) today shared details of its participation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13 2022 at the Ernest N. Morial Convention Center in New Orleans, La. Exscientia scientists will present new research in three poster presentations. “We are looking forward to meeting with some of the world’s leading cancer clinicians and researchers at... Read More

Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development strategy for Exscientia’s portfolio of investigational medicines. Exscientia’s drug discovery platform utilises patient-based translational models and AI-driven molecule design to optimise drug candidates for specific patient... Read More

Exscientia plc (Nasdaq: EXAI) - Recent advancements in the Company’s pipeline, collaborations and operations as well as financial results for the fourth quarter and full year 2021 are summarised below. In addition, Exscientia will host a conference call on Thursday, March 24 at 12:30 p.m. GMT / 8:30 a.m. ET to provide an... Read More

Exscientia (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2021, on Wednesday, March 23, 2022 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. ET on Thursday, March 24, 2022, to provide an overview of the company's unique end-to-end technology platform and Exscientia's work to fully... Read More

Exscientia (Nasdaq: EXAI) and the University of Oxford Target Discovery Institute (Oxford TDI) today announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs. The Xcellomics program was created by the two Oxford-based institutions to expedite early-stage... Read More

Exscientia (Nasdaq: EXAI) today announced the acceptance of three abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA. “The abstracts highlighted at AACR demonstrate the potential of our functional precision oncology tools to improve clinical and patient outcomes by... Read More

Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO and Ben Taylor, CFO & Chief Strategy Officer, will participate in fireside chats at the following investor conferences in March: Morgan Stanley EMEA HealthTech Conference: Date: Tuesday, March 1, 2022 Time: 9:00 a.m. ET / 2:00 p.m. GMT Location: Virtual Barclays Global Healthcare Conference: Date: Wednesday, March 16, 2022... Read More

Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Exscientia as Chief Scientist of Biologics AI. In this newly created role, she will focus on the application of artificial intelligence (AI), machine learning, and the design of protein structures in the discovery and development of novel drug candidates. Professor Deane joins Exscientia’s technology leadership team, reporting to Chief Technology... Read More

Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilizing actual patient samples. The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel bispecific small molecule candidate capable of... Read More

Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO, Ben Taylor, CFO & Chief Strategy Officer, and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT). A live webcast of the fireside chat will be available on the Company’s... Read More

Exscientia (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations as well as financial results for the third quarter ended September 30, 2021 are summarised below. In addition, Exscientia will host a conference call on Thursday, November 18 at 1:30 p.m. GMT / 8:30 a.m. ET to provide detail... Read More

Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, will report financial results for the third quarter ended September 30, 2021, on Wednesday, November 17, 2021 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. ET on... Read More

Exscientia (Nasdaq: EXAI), the Medical University of Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, today announced publication in Cancer Discovery, a journal of the American Association of Cancer Research, of final results from the EXALT-1 trial. The study, titled “ Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Haematological Cancers and... Read More

Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the closing of its previously-announced upsized initial public offering in the United States of 15,927,500 American Depositary Shares (“ADSs”) representing 15,927,500 ordinary shares, including 2,077,500 ADSs sold pursuant to the... Read More